1. Bundhun PK, Wu ZJ, Chen M-H. Coronary artery bypass surgery compared with percutaneous coronary interventions in patients with insulin-treated type 2 diabetes mellitus: a systematic review and metaanalysis of 6 randomized controlled trials. Cardiovascular Diabetology. 2016;15(1):2. DOI: 10.1186/s12933-015-0323-z
2. Koskinas KC, Siontis GCM, Piccolo R, Franzone A, Haynes A, RatWirtzler J et al. Impact of Diabetic Status on Outcomes After Revascularization with Drug-Eluting Stents in Relation to Coronary Artery Disease Complexity: Patient-Level Pooled Analysis of 6081 Patients. Circulation: Cardiovascular Interventions. 2016;9(2):e003255. DOI: 10.1161/CIRCINTERVENTIONS.115.003255
3. Tsai TT, Messenger JC, Brennan JM, Patel UD, Dai D, Piana RN et al. Safety and Efficacy of Drug-Eluting Stents in Older Patients with Chronic Kidney Disease. Journal of the American College of Cardiology. 2011;58(18):1859–69. DOI: 10.1016/j.jacc.2011.06.056
4. Enriquez JR, Parikh SV, Selzer F, Jacobs AK, Marroquin O, Mulukutla S et al. Increased Adverse Events After Percutaneous Coronary Intervention in Patients With COPD: insights from the National Heart, Lung, and Blood Institute dynamic registry. Chest. 2011;140(3):604–10. DOI: 10.1378/chest.10-2644
5. Andell P, Sjögren J, Batra G, Szummer K, Koul S. Outcome of patients with chronic obstructive pulmonary disease and severe coronary artery disease who had a coronary artery bypass graft or a percutaneous coronary intervention. European Journal of Cardio-Thoracic Surgery. 2017;52(5):930–6. DOI: 10.1093/ejcts/ezx219
6. Șerban RC, Hadadi L, Șuș I, Lakatos EK, Demjen Z, Scridon A. Impact of chronic obstructive pulmonary disease on in-hospital morbidity and mortality in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention. International Journal of Cardiology. 2017; 243:437–42. DOI: 10.1016/j.ijcard.2017.05.044
7. Global Initiative for Chronic Obstructive Lung Disease 2021. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2021 Report. Available at: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT2021-v1.1-25Nov20_WMV.pdf.
8. Аверков О.В., Дупляков Д.В., Гиляров М.Ю., Новикова Н.А., Шахнович Р.М., Яковлев А.Н. и др. Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):251-310. DOI: 10.15829/29/1560-4071-2020-4103
9. Jatene T, Biering-Sørensen T, Nochioka K, Mangione FM, Hansen KW, Sørensen R et al. Frequency of Cardiac Death and Stent Thrombosis in Patients with Chronic Obstructive Pulmonary Disease Undergoing Percutaneous Coronary Intervention (from the BASKET-PROVE I and II Trials). The American Journal of Cardiology. 2017;119(1):14–9. DOI: 10.1016/j.amjcard.2016.09.013
10. Зафираки В.К., Космачева Е.Д. Пациент с ишемической болезнью сердца и хронической обструктивной болезнью легких в эпоху эндоваскулярных вмешательств на коронарных артериях. – М.-Краснодар: Кубанский Государственный Медицинский Университет, 2019. - 286с. ISBN 978-5-903252-12-1
11. Goto T, Shimada YJ, Faridi MK, Camargo CA, Hasegawa K. Incidence of Acute Cardiovascular Event After Acute Exacerbation of COPD. Journal of General Internal Medicine. 2018;33(9):1461–8. DOI: 10.1007/s11606-018-4518-3
12. Sand JMB, Leeming DJ, Byrjalsen I, Bihlet AR, Lange P, Tal-Singer R et al. High levels of biomarkers of collagen remodeling are associated with increased mortality in COPD – results from the ECLIPSE study. Respiratory Research. 2016;17(1):125. DOI: 10.1186/s12931-016-0440-6
13. Прокофьева Т.В., Липницкая Е.А., Кузьмичев Б.Ю., Полунина О.С., Воронина Л.П., Полунина Е.А. Влияние хронической обструктивной болезни легких на уровень гомоцистеинемии и состояние коронарных сосудов у больных инфарктом миокарда. Туберкулез и болезни легких. 2019; 97(10):12-8. DOI: 10.21292/2075-1230-2019-97-10-12-18
14. Maclay JD, McAllister DA, MacNee W. Cardiovascular risk in chronic obstructive pulmonary disease. Respirology. 2007;12(5):634–41. DOI: 10.1111/j.1440-1843.2007.01136.x
15. Portillo K, Abad-Capa J, Ruiz-Manzano J. Enfermedad pulmonar obstructiva crónica y ventrículo izquierdo. Archivos de Bronconeumología. 2015;51(5):227–34. DOI: 10.1016/j.arbres.2014.03.012
16. Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EFM. Systemic Effects of Smoking. Chest. 2007;131(5):1557–66. DOI: 10.1378/chest.06-2179
17. Yawn BP, Keenan JM. COPD—The Primary Care Perspective: Addressing Epidemiology, Pathology, Diagnosis, Treatment of Smoking’s Multiple Morbidities and the Patient’s Perspective. COPD: Journal of Chronic Obstructive Pulmonary Disease. 2007;4(1):67–83. DOI: 10.1080/15412550601169562
18. Vanfleteren LEGW, Spruit MA, Groenen MTJ, Bruijnzeel PLB, Taib Z, Rutten EPA et al. Arterial stiffness in patients with COPD: the role of systemic inflammation and the effects of pulmonary rehabilitation. European Respiratory Journal. 2014;43(5):1306–15. DOI: 10.1183/09031936.00169313
19. Man SFP, Van Eeden S, Sin DD. Vascular Risk in Chronic Obstructive Pulmonary Disease: Role of Inflammation and Other Mediators. Canadian Journal of Cardiology. 2012;28(6):653–61. DOI: 10.1016/j.cjca.2012.06.013
20. Rabinovich RA, MacNee W. Should we treat chronic obstructive pulmonary disease as a cardiovascular disease? Expert Review of Respiratory Medicine. 2015;9(4):459–72. DOI: 10.1586/17476348.2015.1070099
21. Wang R, Li J-Y, Cao Z, Li Y. Mean platelet volume is decreased during an acute exacerbation of chronic obstructive pulmonary disease. Respirology. 2013;18(8):1244–8. DOI: 10.1111/resp.12143
22. Fimognari FL, Scarlata S, Conte ME, Incalzi RA. Mechanisms of atherothrombosis in chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease. 2008;3(1):89–96. DOI: 10.2147/copd.s1401